SBIR/STTR Research Award

human Microvessel Culture System (hMCS)

Award identifier 4d1e352a2d870190752c939df1e22ed69494c4c61084f1baf250a49d864554fdAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,509

Program and phase

STTR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ANGIOMICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PA12-089
Topic code
NHLBI

Research abstract

DESCRIPTION (provided by applicant): Human Microvessel Culture System (hMCS) Angiogenesis-targeting therapies, either inhibiting or promoting new vessel growth, have the potential for treating numerous diseases including cancer, eye diseases, cardiac and peripheral vascular disease, skin disorders, fibro-proliferative diseases, and inflammatory conditions such as arthritis. Furthermore, growing evidence indicates that for many of these diseases combinations of agents targeting multiple different vascular activities are proving more efficacious. As demand and complexity increases for these therapies, there is a growing need for more informative assays of relevant vascular growth and stability. Ideally, such an assay should recapitulate as much of the in vivobiological process as possible, while maintaining experimental simplicity and cost effectiveness. Angiomics, Inc. was founded on proven technology based on the manipulation and culturing of isolated microvessels from a variety of tissues. Utilizing rodentsources, this microvessel culture system has been used extensively and effectively as a more comprehensive experimental and discovery platform for a variety of vascular-related activities and therapies. Because the system utilizes intact microvessels, angiogenesis is more accurately recapitulated in both the culture and in vivo settings. In this system, true neovessels sprout and grow from intact microvessels within a 3-D matrix environment. Consequently, all angiogenesis-relevant activities/elements including perivascular cell behavior are present and integrated in the assay. The overall objective of this proposal is to adapt this proven and versatile microvessel culture system to support human microvessel viability and activity to add utility and value tothe platform. It is guided by two Objectives tha 1) identify media components, guided by the rodent system, and 2) evaluate combinations of candidate growth factors or hypoxia factors that will support human microvessel viability and angiogenesis in culture. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Human Microvessel Culture System (hMCS) Comprehensive yet readily performed in vitro angiogenesis assays are needed as the demand for more complex vascular-targeting therapies rises. This project will adapt a proven experimental platform involving 3-D cultures of isolated microvessels to utilize human microvessels thereby expanding its utility to include the research and development of new and complex vascular-targeting drug therapies.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.